

References

I-250

1. Inclisiran (Leqvio) , injection, for subcutaneous use [package insert], Novartis Pharmaceuticals Co. East Hanover, NJ. Revised 12/2021.
2. Micromedex DrugDex Compendium®. 2022. Inclisiran.
3. Clinical Pharmacology™ Compendium. 2022. Tampa FL: Gold Standard, Inc. Inclisiran.
4. Inclisiran In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated January 14, 2022
5. Leiter LA, Teoh H, Kallend D, et al. Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: The ORION-1 randomized clinical trial. *Diabetes Care*. 2019;42(1):173-176.
6. Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. *JAMA Cardiol*. 2019;4(11):1067-1075.
7. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. *N Engl J Med*. 2020 Apr 16;382(16):1520-1530.
8. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. *N Engl J Med*. 2020;382(16):1507-1519.
9. Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. *Mayo Clin Proc*. 2020;95(1):77-89.